LDN
LDN Price range: $ 81,00 through $ 266,00
Back to products
Levitra
Levitra Price range: $ 40,00 through $ 500,00

Leukeran

Price range: $ 60,00 through $ 1 224,00

Leukeran is a potent chemotherapy medication primarily used in the treatment of various types of cancer. Classified as an alkylating agent, this medication works effectively by interfering with the DNA of cancer cells to inhibit their reproduction and growth. The drug is widely recognized for its efficacy in managing chronic lymphocytic leukemia and certain types of non-Hodgkin’s lymphoma. It is also frequently utilized to treat Hodgkin’s disease, providing a targeted approach to managing malignant lymphoid tissues. Available in convenient tablet form, Leukeran serves as an essential therapeutic option for patients requiring systemic treatment for these specific oncological conditions.

Active substance: Chlorambucil
SKU: Leukeran Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Leukeran (chlorambucil) belongs to the class of antineoplastic agents known as nitrogen mustard alkylating agents. It is an oral prescription medication indicated for the management of specific hematologic malignancies under the supervision of a qualified oncologist.

As a systemic cytotoxic therapy, treatment requires strict adherence to prescribed dosing protocols alongside regular monitoring of peripheral blood counts. In accordance with U.S. federal law, this medication is available exclusively by prescription from a licensed healthcare provider.

Overview and Clinical Profile

Basic Information

Drug Name Leukeran
Active Ingredient Chlorambucil
Therapeutic Class Antineoplastic agent (nitrogen mustard alkylating agent)
Dosage Form Oral tablet (2 mg)
Route of Administration Oral
Primary Purpose Palliative treatment of chronic lymphocytic leukemia and select malignant lymphomas
Prescription Status Prescription (Rx) only

What it’s used for

Chlorambucil is approved by the U.S. Food and Drug Administration (FDA) for the palliative treatment of chronic lymphocytic leukemia (CLL), as well as malignant lymphomas, including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is utilized to induce clinical remission or control tumor burden in these specific lymphatic malignancies. Leukeran is typically prescribed when systemic therapy is required to manage progressive disease. Any off-label applications, such as use in refractory nephrotic syndrome or specific non-malignant autoimmune conditions, represent unapproved uses that require specialized medical evaluation and individual risk-benefit assessments by the treating physician.

How the drug works

Leukeran exerts its therapeutic activity as a bifunctional alkylating agent. Upon entry into systemic circulation, the active substance attaches alkyl groups to cellular components, primarily cross-linking double-stranded DNA. This chemical modification disrupts normal base pairing, inhibits nucleic acid synthesis, and prevents cellular replication during DNA transcription and cell division. Because rapidly dividing lymphoid cells demonstrate heightened sensitivity to DNA cross-linking, the drug selectively induces cytotoxic cell death in malignant lymphocytic lines. While its activity affects both resting and dividing cells, the primary antiproliferative effect interferes with the uncontrolled accumulation of abnormal white blood cells.

How it’s absorbed and eliminated

Following oral administration, chlorambucil is rapidly and almost completely absorbed from the gastrointestinal tract. Peak plasma concentrations are typically attained within one to two hours after ingestion. The drug undergoes extensive hepatic metabolism, being converted principally via beta-oxidation into its primary active metabolite, phenylacetic acid mustard. Both chlorambucil and its active metabolite bind extensively to plasma proteins, predominantly serum albumin. The terminal elimination half-life of chlorambucil is relatively short, averaging approximately 1.5 hours, whereas the phenylacetic acid derivative exhibits a longer half-life of roughly 2.5 hours. Metabolic derivatives are predominantly cleared through urinary excretion.

Dosing schedule

Dosage of Leukeran must be carefully individualized based on clinical response, body weight, and routine hematologic evaluation. For initiation of therapy in chronic lymphocytic leukemia or malignant lymphomas, dosage schedules generally range from short-course pulse regimens to daily maintenance administration as determined by the prescribing oncologist. Administration should occur at consistent daily times, typically on an empty stomach or as advised by a healthcare professional. Periodic full blood counts–including total white blood cell, absolute neutrophil, and platelet counts–are mandatory during therapy. Dose adjustments or temporary treatment interruption may be required if severe bone marrow depression develops.

Compatibility with other medicines

Leukeran can interact with several classes of medications, altering therapeutic efficacy or increasing toxicities. Concurrent use with other bone marrow suppressants or myelosuppressive chemotherapeutic agents heightens the risk of severe leukopenia and thrombocytopenia. Administration of live viral or bacterial vaccines during alkylating agent therapy is contraindicated or strongly discouraged due to immunosuppression, which can diminish vaccine response and increase the risk of vaccine-derived infection. Concomitant administration of uricosuric agents (such as allopurinol) may be required to manage rapid hyperuricemia resulting from tumor lysis, though blood pressure and renal parameters require monitoring. Patients should inform their oncology team of all prescription drugs, over-the-counter products, and dietary supplements being taken.

Safety, Precautions, and FAQ

Adverse reactions

The principal dose-limiting adverse reaction associated with Leukeran is myelosuppression, manifesting as leukopenia, neutropenia, thrombocytopenia, and anemia. Gastrointestinal disturbances are also reported, including nausea, vomiting, diarrhea, and oral ulceration. Dermatologic reactions such as skin rashes, urticaria, and rare severe cutaneous toxicities can occur. Neurological effects, including tremors, twitching, muscle spasms, and central nervous system excitation (including seizures in pediatric or predisposed patients), have been documented. Long-term adverse risks include gonadal dysfunction, resulting in amenorrhea or azoospermia, as well as secondary malignancies such as acute leukemia following extended cumulative exposure.

Red flags

Immediate medical evaluation is necessary if signs of serious complications develop during treatment. Patients should report urgent red flag symptoms to emergency medical services or their oncology care provider without delay.

Critical Red Flags

Symptom / Sign Clinical Implication
Fever, chills, sore throat, or signs of acute infection May indicate severe neutropenia requiring immediate hematologic evaluation
Unusual bleeding, petechiae, or easy bruising May signal severe thrombocytopenia and increased bleeding risk
Severe shortness of breath, sudden cough, or fever Possible pulmonary toxicity or interstitial pneumonitis
Severe skin rash, blistering, or mucosal lesions Potential severe cutaneous adverse reaction requiring therapy cessation
Unexplained seizures, tremors, or muscle twitching Central nervous system toxicity requiring immediate intervention

Important precautions

Leukeran carries major warnings regarding hematologic toxicity and carcinogenic potential. Severe, persistent bone marrow hypoplasia can occur; therefore, blood counts must be monitored weekly or biweekly. As an alkylating agent, chlorambucil is mutagenic and teratogenic. It is classified as pregnancy category D; use during pregnancy can cause fetal harm. Female and male patients of reproductive potential must utilize effective contraception during treatment and for a specified period thereafter. Breastfeeding is not recommended during therapy due to potential excretion into human milk and serious adverse reactions in nursing infants. Pediatric use requires extreme caution due to heightened risk of seizure activity. Elderly patients require careful dosage selection and renal function monitoring.

If you skip a dose

If a scheduled dose of Leukeran is missed, the patient should contact their oncology provider or pharmacist for instructions rather than taking a double dose. If the next scheduled dose is several hours away, the missed tablet may be taken as soon as remembered, provided the clinician has advised this strategy. However, if it is close to the time of the next scheduled dose, skip the missed dose and resume the regular dosing schedule. Never double the dose to make up for a missed tablet, as this elevates the risk of severe acute bone marrow suppression.

Storage and expiration

Leukeran tablets must be stored under refrigeration between 2°C and 8°C (36°F to 46°F) to maintain stability and potency, protected from light and moisture. The tablets should be kept in their original container with the child-resistant closure tightly secured. Safe handling of cytotoxic drugs is required: caregivers should avoid touching crushed or broken tablets and wash hands thoroughly after handling. Keep out of reach of children and pets. Do not use past the expiration date printed on the packaging, and dispose of unused cytotoxic medication according to hazardous pharmaceutical waste standards or local pharmacy take-back programs.

Patient Resources and Questions

What to ask your provider

When starting treatment with Leukeran, patients and caregivers should maintain open communication with their healthcare team. Key questions to discuss with your doctor or pharmacist include:

  • How often will complete blood count (CBC) tests be required to monitor my bone marrow function?
  • What specific steps should I take if I develop a fever or signs of an infection while in Texas or elsewhere?
  • How does this medication interact with my existing prescription and over-the-counter medications?
  • What precautions should be taken regarding fertility preservation and family planning before initiating treatment?
  • What are the exact home storage guidelines for maintaining refrigerator temperatures between 36°F and 46°F?

Common Questions

Is it safe to consume alcohol while taking Leukeran?

Alcohol does not have a direct chemical interaction with chlorambucil, but concurrent intake can exacerbate gastrointestinal irritation and liver burden. Because both alcohol and chemotherapy agents are metabolized by the liver, consuming alcohol may increase the risk of hepatotoxicity or nausea. Patients should consult their oncologist regarding safe dietary guidelines during treatment.

How long does treatment with Leukeran usually continue?

The duration of treatment depends on the specific malignancy, disease stage, therapeutic response, and patient tolerance. Short pulse courses may last several days repeated at interval cycles, while continuous maintenance protocols can span several weeks or months. The oncologist periodically reevaluates treatment duration based on peripheral blood counts and clinical response.

Can Leukeran affect fertility in both men and women?

Yes. Chlorambucil is known to cause gonadal suppression, which may lead to irreversible infertility. Male patients may experience oligospermia or azoospermia, while female patients may develop amenorrhea or ovarian failure. Reproductive risks and fertility preservation options should be discussed with a healthcare provider prior to starting therapy.

What should I do if I experience nausea after taking my dose?

Mild to moderate nausea can occur with oral antineoplastic agents. Taking the medication on an empty stomach or at bedtime may help reduce gastrointestinal distress in some patients. If nausea persists or interferes with oral intake, the prescribing physician may recommend antiemetic medications to manage symptoms effectively.

Is routine blood testing strictly necessary during treatment?

Yes. Regular peripheral blood count monitoring is mandatory during Leukeran therapy due to the risk of severe bone marrow suppression. Blood tests allow the clinical team to detect leukopenia, neutropenia, or thrombocytopenia early and adjust or temporarily hold dosing to prevent severe complications.

In accordance with FDA requirements.

Information on this page is for reference and does not replace an assessment by a licensed healthcare professional.

Additional information
Dosage

2mg

Package

10 pills

,

20 pills

,

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία